Organogenesis Holdings Inc.: directors' dealings · United States · SEC (Form 4)

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a U.S.-based regenerative medicine company listed on the NASDAQ market in the United States. For French-, Belgian- and Swiss-based investors, the company can be viewed as a specialized healthcare platform focused on wound healing, tissue repair, and selected surgical and sports medicine applications. It was founded in 1985 as a spin-off from regenerative technology developed at the Massachusetts Institute of Technology (MIT), giving it a long operating history in biomaterials and biologics. Its corporate headquarters are in Canton, Massachusetts, with additional U.S. sites in Alabama, Florida, and California. The company also states that it manufactures its products in the United States, which is relevant for supply-chain control, quality positioning, and customer confidence in regulated healthcare markets. Organogenesis’ business is organized around two main product areas. The first is Advanced Wound Care, which addresses chronic and complex wounds through a portfolio that includes well-known brands such as Apligraf, Dermagraft, PuraPly AM, NuShield, Affinity and other placental or collagen-based solutions. The second is Surgical & Sports Medicine, where the company markets products designed for operative, orthopedic, and sports medicine use, including NuShield, PuraForce, PuraPly SX and PuraPly MZ. This two-pronged model gives Organogenesis exposure to multiple points in the care continuum, from chronic wound management to surgical wound coverage and soft tissue support. From a competitive standpoint, Organogenesis differentiates itself through a broad product portfolio, a long-standing clinical footprint, and a strong commercial presence in the U.S. Its history reflects both internal innovation and selective acquisitions: Apligraf was FDA-approved in the late 1990s, PuraPly was launched in 2015, and the 2017 acquisition of NuTech Medical expanded the company into surgical and sports medicine. The company also established a European office in Switzerland, which indicates a limited but meaningful international presence. Recent developments have been mixed but important. In early 2025, the company reported a decline in first-quarter net revenue, yet third-quarter 2025 results showed record revenue and the fourth quarter of 2025 was also described as record-setting, driven primarily by strong growth in Advanced Wound Care. In March 2025, Organogenesis highlighted a significant CMS payment reform step for skin substitutes/cellular and tissue-based products, a potentially important catalyst for reimbursement visibility in the sector. At the same time, management disclosed in July 2025 that the second Phase 3 study of ReNu did not meet its primary endpoint, underscoring that pipeline execution remains a risk. Overall, ORGO is a niche healthcare equity on the NASDAQ with meaningful commercial scale in the U.S., attractive product depth, and high sensitivity to reimbursement policy, clinical adoption, and execution in a specialized medical market.